Tissue Chips in Space 2.0: Translational Multi-Organ Tissue Chip Systems for Drug Efficacy, Toxicity Testing, and Personalized Medicine in Human Health, Aging and Associated Diseases (UG3/UH3 Clinical Trial Not Allowed)
ID: 355661Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $750K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355661

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-TR-24-025.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Tissue Chips in Space 2.0," aimed at developing translational multi-organ automated microphysiological systems (MPS) to study the effects of microgravity on human health, particularly in relation to aging and age-related diseases. The initiative will utilize the International Space Station National Laboratory (ISS-NL) to gain insights into human physiology under prolonged microgravity conditions, with a focus on creating robust organ systems that can model aging-associated dysfunction and evaluate drug efficacy and safety in space. This program is significant for advancing our understanding of age-related conditions and therapeutic interventions, ultimately informing clinical practices both on Earth and in space. The total funding available is approximately $5.6 million, with a close date for applications set for October 18, 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-TR-24-025-Full-Announcement.html
    RFA-TR-24-025.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces the funding opportunity titled "Tissue Chips in Space 2.0: Translational Multi-Organ Tissue Chip Systems." This initiative aims to develop automated microphysiological systems (MPS) to study the effects of microgravity on human health, particularly as it relates to aging and age-related diseases. The program will utilize the International Space Station National Laboratory (ISS-NL) to provide insights into human physiology under prolonged microgravity conditions. The program consists of two phases: the initial UG3 phase focuses on developing robust organ systems capable of modeling aging-associated dysfunction, while the UH3 phase builds upon successful UG3 projects to evaluate biomarkers, drug efficacy, and safety in space. Collaboration with the Center for the Advancement of Science in Space (CASIS) and an Implementation Partner is required to facilitate research and payload integration for spaceflight. The anticipated funding includes $5M from the National Center for Advancing Translational Sciences (NCATS) and $600,000 from the National Institute on Aging (NIA) for a total of approximately 4-6 awards. Applications are encouraged to incorporate diverse populations and aim for innovative approaches, which can enhance our understanding of age-related conditions and therapeutic interventions, ultimately informing clinical practices both on Earth and in space.
    Similar Opportunities
    Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Miniaturization and Automation of Tissue Chip Systems" (MATChS), aimed at advancing the development of automated and miniaturized microphysiological systems (MPS) for drug discovery and biomedical research. This funding opportunity encourages U.S. small business concerns (SBCs) to propose innovative solutions that enhance the efficiency and reliability of tissue chip technologies, with a focus on reducing complexity and costs while facilitating higher throughput. Approximately $2.15 million is allocated for FY 2024 to support projects that collaborate with NIH staff to achieve defined milestones and pathways to commercialization. Interested applicants must submit their proposals by February 23, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 grant mechanism to support the development of next-generation human cell-derived microphysiological systems (MPS) that accurately replicate the architectures and functions of the human nervous system. This initiative aims to encourage high-risk, high-reward exploratory research, particularly relevant for addressing complex nervous system disorders, and is open to a diverse range of eligible applicants, including educational institutions, non-profits, and governmental entities. The funding, capped at $275,000 over a two-year period, emphasizes collaboration among experts in neurobiology, engineering, and ethics, and applications must adhere to NIH data management and sharing policies. Interested parties can find more information and submit inquiries via grantsinfo@nih.gov, with the application deadline set for January 7, 2026.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)," aimed at advancing research in human cell-derived microphysiological systems (MPS) that replicate complex nervous system architectures and functions. This initiative seeks innovative applications that address technological barriers in studying nervous system development and diseases, with a focus on improving physiological relevance and circuit-level activity in existing assays. The funding is open to a wide range of eligible applicants, including higher education institutions and non-profits, with a project period of up to five years and no cost-sharing requirement. Interested parties should note that the application deadline is January 7, 2026, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the announcement page at https://grants.nih.gov/grants/guide/pa-files/PAR-23-046.html.
    Research Resource for Human Organs and Tissues (U42 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research Resource for Human Organs and Tissues" through a cooperative agreement mechanism (U42), aimed at supporting a program that provides and facilitates the availability of human tissues and organs for biomedical research. The initiative seeks to enhance the procurement, preservation, and distribution of diverse biospecimens, both normal and diseased, to aid researchers in understanding various diseases and addressing public health priorities. Applicants must demonstrate a proven track record in managing a human tissue and organ research resource, with direct costs capped at $720,000 over a potential five-year project period. The application period opens on December 24, 2024, with a submission deadline of September 25, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Miniaturization and Automation of Tissue Chip Systems (MATChS) (UT1/UT2 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Miniaturization and Automation of Tissue Chip Systems (MATChS)" aimed at supporting Small Business Technology Transfer (STTR) applications. This initiative seeks to enhance microphysiological systems that replicate organ functions, focusing on the development of compact, automated systems for real-time analysis of tissue health to improve drug discovery and precision medicine. Eligible U.S.-based small businesses can apply for funding of up to $2.15 million for Phase I and Phase II awards, with proposals required to demonstrate innovation, a clear commercialization strategy, and collaboration with NIH staff. Interested applicants should refer to the full announcement available at NIH Grants and note that the application deadline is February 23, 2026.
    Organs-on-a-Chip in Dental, Oral, and Craniofacial Research (DOC-OoCs) (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Organs-on-a-Chip in Dental, Oral, and Craniofacial Research (DOC-OoCs) (R01 Clinical Trial Not Allowed)" aimed at advancing the development of organ-on-a-chip (OoC) technologies for dental, oral, and craniofacial research. This initiative seeks to support interdisciplinary research that validates these microfluidic systems for disease modeling and pre-clinical efficacy studies, with the goal of establishing OoC technologies as viable alternatives to animal models. A total of $2 million is allocated for 4-5 grants, with individual project budgets capped at $500,000 annually and a project duration of up to five years. Applications are due by November 19, 2024, and interested parties can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Facilitating Preclinical and Early Phase Human Studies for New Therapeutics (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for facilitating preclinical and early phase human studies for new therapeutics, specifically targeting aging-related conditions. This initiative aims to advance T1 translational aging research, focusing on therapeutics that progress from preclinical stages to first-in-human trials, addressing conditions such as sarcopenia and heart failure with preserved ejection fraction (HFpEF). The funding opportunity, categorized under health-related activities, will utilize the UG3/UH3 Cooperative Agreement mechanism, with an estimated total program funding of $2.5 million. Interested applicants should prepare to submit their applications by fall 2024, with the NOFO expected to be published in summer 2024 and awards anticipated by July 2025.
    Organs-on-a-Chip in Dental, Oral, and Craniofacial Research (DOC-OoCs) (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering an R21 exploratory/developmental grant aimed at funding innovative research in the development of organ-on-a-chip (OoC) models for dental, oral, and craniofacial (DOC) applications. The primary objective is to validate these microfluidic systems for disease modeling and pre-clinical efficacy studies, promoting a multidisciplinary approach that integrates fields such as bioengineering and computational biology. This initiative is crucial for enhancing drug testing and improving preclinical models, ultimately leading to better clinical trial designs and reducing reliance on animal testing. The total funding available for FY 2025 is $1 million, with individual awards capped at $275,000 over two years. Applications are due by November 19, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for Complex Integrated Multi-Component Projects in Aging Research, designated as a U19 Clinical Trial Optional grant. This initiative aims to support large-scale, multidisciplinary research projects that address common questions related to aging, encouraging collaboration among investigators from various institutions. The program is particularly significant as it seeks to advance scientific knowledge in aging while addressing health disparities and promoting innovative research approaches. Interested applicants, including higher education institutions, nonprofits, and government agencies, can submit proposals until September 25, 2025, with a maximum project period of five years. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-213.html.
    Research Infrastructure Development for Interdisciplinary Aging Studies (R61/R33 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research Infrastructure Development for Interdisciplinary Aging Studies (R61/R33 - Clinical Trial Optional)" aimed at advancing the science of aging through innovative research infrastructure. This initiative invites applications from a diverse range of eligible institutions to develop sustainable frameworks that address critical interdisciplinary questions in aging, with a focus on areas such as machine learning applications, health disparities, and behavioral aspects of aging. The funding mechanism provides up to five years of support, including two years for initial developmental activities and up to three years for expanded activities, with an award ceiling of $500,000. Interested applicants can find more information and application guidelines at the NIH website, and must submit their proposals by December 2, 2025, to be considered for this discretionary grant opportunity.